Two Health IT Veterans Join XSOLIS’ Board

NASHVILLE, Tenn., Nov. 20, 2019 /PRNewswire/ — XSOLIS, the company using artificial intelligence to redesign utilization management between payers and providers, today announced two additions to its Board of Directors: Doug Ghertner and George Lazenby, IV. Their additions to the Board were approved unanimously on November 18, 2019.

Mr. Ghertner currently serves as CEO of IVX Health, a national provider of infusion and injection therapy for individuals with complex chronic conditions. Prior to joining IVX Health, he served as CEO of Change Healthcare from 2011 to 2014 before its acquisition by Emdeon in 2014, at which point he remained on as Chief Sales Officer until 2017.

Mr. Lazenby co-founded OrderInsite and currently serves as its CEO. He also served as CEO of Emdeon, which he saw through 15 completed acquisitions, initial public offering in August 2009 and successful sale in 2011. Lazenby also serves as Board Member for CarePayment, ProxsysRx, and Concert Genetics.

“The energy and expertise Doug and George bring to bear are exciting for our organization,” said Joan Butters, CEO and co-founder of XSOLIS. “We share a common goal of uniting payers, providers and patients through technology and analytics. Doug and George will help us deliver on that vision strategically and swiftly.”

About XSOLIS

XSOLIS is a healthcare technology firm focused on improving healthcare operations through cognitive computing. Partnering with some of the most forward-thinking healthcare organizations across the nation, XSOLIS transforms the utilization management process between payers and providers: XSOLIS analytics and artificial intelligence form a common framework for objective, holistic determinations of medical necessity and automate much of the administrative burden within the review process. For more information, visit www.xsolis.com.

 

View original content:http://www.prnewswire.com/news-releases/two-health-it-veterans-join-xsolis-board-300962309.html

SOURCE XSOLIS

Staff

Recent Posts

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

23 hours ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

23 hours ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

23 hours ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

23 hours ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

23 hours ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…

23 hours ago